Resuscitec

Resuscitec GmbH, founded in 2010 and based in Freiburg, Germany, is a medical device company that focuses on developing cutting-edge technology for emergency and intensive care medicine. As a spin-off of the University Hospital Freiburg, the company has a strong foundation in medical research and innovation. Resuscitec's core mission, as expressed in their slogan "Life is our mission," is to become a global leader in extracorporeal cardiopulmonary resuscitation (ECPR). The company's flagship technology, controlled patient-specific reperfusion of the whole body (CARL), aims to address the limitations of traditional resuscitation methods in achieving neurologically intact survival following sudden cardiac arrest. By enabling both in- and out-of-hospital multi-professional rescue teams to perform the patient-centric CARL Therapy, Resuscitec is positioned to significantly impact emergency medical care. In January 2016, Resuscitec secured a Series B investment from Zukunftsfonds Heilbronn, signifying investor confidence in the company's vision and technology. With a focus on biotechnology and healthcare, Resuscitec is poised to make a meaningful contribution to the advancement of emergency and intensive care medicine, offering a promising opportunity for potential investors in the healthcare technology sector.